| Hepatitis B virus therapy: What’s the future holding for us? S Manzoor, M Saalim, M Imran, S Resham, J Ashraf World journal of gastroenterology 21 (44), 12558, 2015 | 57 | 2015 |
| PTEN: A potential prognostic marker in virus-induced hepatocellular carcinoma A Khalid, T Hussain, S Manzoor, M Saalim, S Khaliq Tumor Biology 39 (6), 1010428317705754, 2017 | 47 | 2017 |
| Zika virus: immune evasion mechanisms, currently available therapeutic regimens, and vaccines A Asif, S Manzoor, F Tuz-Zahra, M Saalim, M Ashraf, J Ishtiyaq, M Khalid Viral immunology 30 (10), 682-690, 2017 | 31 | 2017 |
| HIV‐1 and hijacking of the host immune system: the current scenario M Imran, S Manzoor, M Saalim, S Resham, J Ashraf, A Javed, AB Waqar Apmis 124 (10), 817-831, 2016 | 28 | 2016 |
| IL-22: a promising candidate to inhibit viral-induced liver disease progression and hepatocellular carcinoma M Saalim, S Resham, S Manzoor, H Ahmad, S Jaleel, J Ashraf, M Imran, ... Tumor Biology 37, 105-114, 2016 | 24 | 2016 |
| Mechanistic study of interaction between IL-22 and HCV core protein in the development of hepatocellular carcinoma among liver transplant recipients S Resham, M Saalim, S Manzoor, H Ahmad, TA Bangash, A Latif, S Jaleel Microbial pathogenesis 142, 104071, 2020 | 8 | 2020 |
| IL-22 in hepatocyte’s survival of Pakistani patients with end stage liver disease: an insight into IL 22 mediated hepato-regenerative pathway M Saalim, S Resham, S Manzoor, H Ahmad, TA Bangash, A Latif, S Jaleel Molecular biology reports 46, 1127-1138, 2019 | 5 | 2019 |
| Interleukin‐28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response S Resham, S Manzoor, M Imran, M Saalim, S Naseem, S Azam Apmis 123 (9), 765-771, 2015 | 5 | 2015 |
| Quantitative evaluation of insulin resistance markers in Pakistani patients suffering from HCV-associated type 2 diabetes mellitus SN Sabir, S Manzoor, F Parvaiz, M Saalim, E Ghani Acta Virol 61 (2), 197-203, 2017 | 4 | 2017 |
